AstraZeneca (AZN) Q3 2024 earnings summary

Executive summary

• Total revenue grew 21% in Q3 and 19% year-to-date to $39.2bn, with core EPS up 27% in Q3 and 11% year-to-date, reflecting strong global demand and profitability focus.

• All focus areas and geographies delivered double-digit growth, with emerging markets outside China now surpassing China in revenue share.

• Upgraded full-year 2024 guidance: both total revenue and core EPS expected to increase by high-teens percentages at constant exchange rates.

• Announced $3.5 billion investment in U.S. manufacturing and R&D to support future growth.

• Significant regulatory approvals and positive late-stage trial readouts across multiple medicines and geographies, including US, EU, and China.

Financial highlights

• Product sales and total revenue increased 19% in the first nine months to $39.2bn; alliance revenue up 50% to $1.5bn, driven by Enhertu and Tezspire.

• Core product sales gross margin was 81.9% for 9M 2024, slightly down from prior year; full-year margin expected to be slightly lower than 2023.

• Operating expenses rose 15% year-to-date, R&D expenses up 18% due to acquisitions and accelerated projects.

• Net cash inflow from operating activities increased 12% to $8,954m for 9M 2024; CapEx up 50% year-over-year, with $1.2bn spent year-to-date.

• Net debt increased by $3.8bn to $26.3bn, net debt-to-EBITDA at 1.8x, reflecting acquisitions and dividend payments.

Outlook and guidance

• Upgraded 2024 guidance: total revenue and core EPS to grow by high-teens percentage at constant exchange rates.

• FX anticipated to have a low single-digit adverse impact on total revenue and mid single-digit on core EPS.

• Confident in achieving $80bn total revenue by 2030 and mid-30s% operating margin by 2026.